Immunization of health-care personnel: Recommendations of the Advisory Committee On Immunization Practices (ACIP)

Morbidity and Mortality Weekly Report

Volumn 60, Issue RR-7, 2011, Pages 1-37

  Shefer, Abigail ^a   Atkinson, William ^a   Friedman, Carole ^a   Kuhar, David T ^b   Mootrey, Gina ^a   Bialek, Stephanie R ^a   Cohn, Amanda ^a   Fiore, Anthony ^c   Grohskopf, Lisa ^a   Liang, Jennifer L ^a   Lorick, Suchita A ^a   Marin, Mona ^a   Mintz, Eric ^b   Murphy, Trudy V ^d   Newton, Anna ^b   Fiebelkorn, Amy Parker ^a   Seward, Jane ^a   Wallace, Gregory ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c Global Ctr for Resolution Research   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ADULT; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HUMAN; IMMUNIZATION; INFECTION CONTROL; MANPOWER; REVIEW; STANDARD;

ADULT; HEALTH FACILITIES; HEALTH PERSONNEL; HUMANS; IMMUNIZATION; INFECTION CONTROL; VACCINES;

EID: 82455171804     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Review

References (329)

1. CDC. Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1997;46(No. RR-18).
2. US Department of Health and Human Services. Definition of health-care personnel (HCP). Available at http://www.hhs.gov/ash/programs/initiatives/vacctoolkit/definition.html. Accessed October 5, 2011.
3. Bolyard EA, Tablan OC, Williams WW, Pearson ML, Shapiro CN, Deitchman SD, Hospital Infection Control Practices Advisory Committee (HICPAC). Guideline for infection control in healthcare personnel, 1998. Infect Control Hosp Epidemiol 1998;19:407-63.
4. CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011;60(No. RR-2).
5. Dayan GH, Ortega-Sánchez IR, LeBaron CW, Quinlisk MP. Iowa Measles Response Team. The cost of containing one case of measles: the economic impact on the public health infrastructure-Iowa, 2004. Pediatrics 2005;116:e1-4.
6. CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR 2006;55(No. RR-17).
7. CDC. Local health department costs associated with response to a school-based pertussis outbreak-Omaha, Nebraska, September-November 2008. MMWR 2011;60:5-9.
8. American Hospital Association. Immunization: management advisory on health care delivery. Chicago, IL American Hospital Association; 1992.
9. CDC. State immunization laws for healthcare personnel and patients. Available at http://www2a.cdc.gov/nip/StateVaccApp/statevaccsApp/default.asp. Accessed October 5, 2011.
10. Miller BL, Ahmed F, Lindley MC, Wortley PM. Institutional requirements for influenza vaccination of healthcare personnel: results from a nationally representative survey of acute care hospitals-United States, 2011. Clin Infect Dis 2011;53(11):1051-9.
11. Beltrami EM, Bolyard EA. Personnel health services. In: Jarvis W, ed. Bennett and Brachman's hospital infections. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:45-63.
12. CDC. Manual for the surveillance of vaccine-preventable diseases. Available at http://www.cdc.gov/vaccines/pubs/surv-manual/index.html. Accessed October 5, 2011.
13. CDC. Summary of notifiable diseases-United States, 2009. MMWR 2009:58(No.53).
14. Beltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev 2000;13:385-407.
15. Werner BG, Grady GF. Accidental hepatitis-B-surface-antigen-positive inoculations. Ann Intern Med 1982;97:367-9.
16. Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week. Lancet 1981;1:550-1.
17. CDC. Viral hepatitis surveillance-2009 surveillance. Available at http://www.cdc.gov/hepatitis/Statistics/2009Surveillance/index.htm. Accessed October 5, 2011.
18. CDC. Surveillance for acute viral hepatitis-United States, 2007. MMWR 2009;58(No. SS-3).
19. Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington, DC: The National Academies Press; 2010.
20. CDC. Achievements in public health: hepatitis B vaccination-United States, 1982-2002. MMWR 2002;51:549-52.
21. CDC. National and state vaccination coverage among children aged 19-35 months-United States, 2010. MMWR 2011;60:1157-63.
22. CDC. National and state vaccination coverage among adolescents aged 13-17 years-United States, 2010. MMWR 2011;60:1117-23.
23. Lu P-J, Byrd KK, Murphy TV, Weinbaum C. Hepatitis B Vaccination coverage among high-risk adults 18-49 years, U.S. 2009. Vaccine 2011;29:7049-57.
24. CDC. Hepatitis surveillance report No. 60. Atlanta, GA: US Department of Health and Human Services, CDC; 2005.
25. Alter MJ, Hadler SC, Margolis MD, et al. The changing epidemiology of hepatitis B in the United States: need for alternative vaccination strategies. JAMA 1990;263:1218-22.
26. Osterholm MT, Garayale SM. Clinical viral hepatitis B among Minnesota hospital personnel: results of a ten-year statewide survey. JAMA 1985;254:3207-12.
27. Thomas DL, Factor SH, Gabon D, et al. Viral hepatitis in health care personnel at the Johns Hopkins Hospital. Arch Intern Med 1993; 153:1705-12.
28. Dienstag JL, Ryan DM. Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization? Am J Epidemiol 1982;115:26-39.
29. Shapiro CN, Tokars JI, Chamberland ME, et al. Use of the hepatitis B vaccine and infection with hepatitis B and C among orthopaedic surgeons. J Bone Joint Surg 1996;78-A:1791-800.
30. Gibas A, Blewett DR, Schoenfled DA, Dienstag JL. Prevalence and incidence of viral hepatitis in health workers in the prehepatitis B vaccination era. Am J Epidemiol 1992;136:603-10.
31. Hadler SC, Doto IL, Maynard JE, et al. Occupational risk of hepatitis B infection in hospital workers. Infection Control 1985;6:24-31.
32. Thompson ND, Perz JF. Eliminating the blood: ongoing outbreaks of hepatitis B virus infection and the need for innovative glucose monitoring technologies. J Diabetes Sci Technol 2009;3:283-8.
33. Klonoff DC, Perz JF. Assisted monitoring of blood glucose: special safety needs for a new paradigm in testing glucose. J Diabetes Sci Technol 2010;4:1027-31.
34. CDC. Transmission of hepatitis B virus among persons undergoing blood glucose monitoring in long-term-care facilities-Mississippi, North Carolina, and Los Angeles County, California, 2003-2004. MMWR 2005;54:220-3.
35. US Department of Labor. Bloodborne pathogens: the standard. Federal Register 1991;60:64175-82.
36. Agerton TB, Mahoney, SJ, Polish UB, Shapiro CN. Impact of the Bloodborne Pathogens Standard on vaccination of healthcare workers with hepatitis B vaccine. Infect Control Hospital Epidemiol 1995; 16:287-91.
37. Simard EP, Miller JT, George PA, et al. Hepatitis B vaccination coverage levels among healthcare workers in the United States, 2002-2003. Infect Control Hosp Epidemiol 2007;28:783-90.
38. Lu PJ, Euler GL. Influenza, hepatitis B, and tetanus vaccination coverage among healthcare personnel in the United States. Am J Infect Control 2011;39:488-94.
39. US Department of Health and Human Services. Proposed Healthy People 2020 objectives. Available at http://www.healthypeople.gov/hp2020/Objectives/TopicAreas.aspx. Accessed October 5, 2011.
40. Dienstag JL, Werner BG, Polk BF, et al. Hepatitis B vaccine in health-care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med 1984;101:34-40.
41. Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986;13(Suppl A):39-45.
42. Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine: report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 1982; 97:362-6.
43. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk for hepatitis B virus infection. Am J Prev Med 1998;15:1-8.
44. Shaw FE Jr, Guess HA, Roets JM, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989;7:425-30.
45. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 1985;254:3187-9.
46. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993;270:2935-9.
47. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009;200:1390-6.
48. Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis 2011;53:68-75.
49. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986;315:209-14.
50. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis 1999;179:489-92.
51. Stevens CE, Toy PT, Taylor PE, Lee T, Yip HY. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. Pediatrics 1992;90(1 Pt 2):170-3.
52. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. Part II: immunization of adults. MMWR 2006;55(No. RR-16).
53. Clemens R, Sanger R, Kruppenbacher J, et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule-results of a post-marketing surveillance. Vaccine 1997;15:349-52.
54. Craven DE, Awdeh ZL, Kunches LM, et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann Intern Med 1986;105:356-60.
55. Goldwater PN. Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 1997;15:353-6.
56. Kim MJ, Nafziger AN, Harro CD, et al. Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine 2003;21:1174-9.
57. Bertino JS Jr, Tirrell P, Greenberg RN, et al. A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders. J Infect Dis 1997; 175:678-81.
58. Weissman JY, Tsuchiyose MM, Tong MJ, Co R, Chin K, Ettenger RB. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA 1988;260:1734-8.
59. Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989;321:708-12.
60. Institute of Medicine. Immunization safety review: hepatitis B vaccine and demyelinating disorders. Washington, DC: The National Academies Press; 2002.
61. Institute of Medicine. Adverse effects of vaccines: evidence and causality. Available at http://www.iom.edu/Reports/2011/Adverse-Effects-of-Vaccines-Evidence-and-Causality.aspx Accessed October 5, 2011.
62. Global Advisory Committee on Vaccine Safety. 12-13 December 2007. Wkly Epidemiol Record 2008;83:37-44.
63. Sundberg JP, Silva KA, Sundberg BA, et al. Recombinant human hepatitis B vaccine initiating alopecia areata: testing the hypothesis using C3H/HeJ mouse model. Vet Dermatol 2009;20:99-104.
64. GlaxoSmithKline Biologicals. Engerix-B [Package insert]. Rixensart, Belgium: GlaxoSmithKline Biologicals; 2010.
65. Merck & Co., Inc. Recombivax HB: hepatitis B vaccine (recombinant) [Package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2011.
66. GlaxoSmithKline Biologicals. Twinrix [Package insert]. Rixensart, Belgium: GlaxoSmithKline Biologicals; 2011.
67. CDC. Hepatitis B vaccine information statement. Available at http://www.cdc.gov/vaccines/pubs/vis/default.htm. Accessed October 5, 2011.
68. Levy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal safety. Am J Perinatol 1991;8:227-32.
69. CDC. Recommendations for preventing transmission of HIV and HBV virus to patients during exposure-prone invasive procedures. MMWR 1991;40(No. RR-8).
70. CDC. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991;40(No. RR-13).
71. CDC. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR 2008;57(No. RR-8).
72. CDC. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001;50 (No. RR-11).
73. Eckman MH, Kaiser TE, Sherman KE. The cost-effectiveness of screening for chronic Hepatitis B infection in the United States. Clin Infect Dis2011;52:1294-306.
74. Thompson WW, Weintraub E, Dhankhar P, et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respi Viruses 2009;3:37-49.
75. CDC. Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR 2010;59:1057-62.
76. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333-40.
77. CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010(No. RR-8).
78. Jain R, Goldman RD. Novel influenza A(H1N1): clinical presentation, diagnosis, and management. Pediatr Emerg Care 2009;25:791-6.
79. Lester RT, McGeer A, Tomlinson G, et al. Use of, effectiveness of, and attitudes regarding influenza vaccine among house staff. Infect Control Hosp Epidemiol 2003;24:839-44.
80. Saxen H,Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J 1999;18:779.
81. Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999; 281:908-13.
82. Malavaud S, Malavaud B, Sandres K, et al. Nosocomial outbreak of influenza virus A (H3N2) infection in a solid organ transplant department. Transplantation 2001;72:535-7.
83. Maltezou HC, Drancourt M. Nosocomial influenza in children. J Hosp Infect 2003;55:83-91.
84. Hall CB, Douglas RG Jr. Nosocomial influenza infection as a cause of intercurrent fevers in infants. Pediatrics 1975;55:673-7.
85. Weinstock DM, Eagan J, Malak SA, et al. Control of influenza A on a bone marrow transplant unit. Infect Control Hosp Epidemiol 2000;21:730-2.
86. Salgado CD, Giannetta ET, Hayden FG, et al. Preventing nosocomial influenza by improving the vaccine acceptance rate of clinicians. Infect Control Hosp Epidemiol 2004;25:923-8.
87. Adal KA, Flowers RH, Anglim AM, et al. Prevention of nosocomial influenza. Infect Control Hosp Epidemiol 1996;17:641-8.
88. Cunney RJ, Bialachowski A, Thornley D, et al. An outbreak of influenza A in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2000;21:449-54.
89. Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. Clin Infect Dis 2003;37:1094-101.
90. Sartor C, Zandotti C, Romain F, et al. Disruption of services in an internal medicine unit due to a nosocomial influenza outbreak. Infect Control Hosp Epidemiol 2002;23:615-9.
91. Saito R, Suzuki H, Oshitani H, et al. The effectiveness of influenza vaccine against influenza a (H3N2) virus infections in nursing homes in Niigata, Japan, during the 1998-1999 and 1999-2000 seasons. Infect Control Hosp Epidemiol 2002;23:82-6.
92. Lemaitre M, Meret T, Rothan-Tondeur M, et al. Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster-randomized trial. J Am Geriatr Soc 2009;57:1580-6.
93. Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 2000;355:93-7.
94. Hayward AC, Harling R, Wetten S, et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ 2006;333:1241.
95. Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997;175:1-6.
96. Thomas RE, Jefferson TO, Demicheli V, et al. Influenza vaccination for health-care workers who work with elderly people in institutions: a systematic review. Lancet Infect Dis 2006;6:273-9.
97. Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database Syst Rev 2010;2:CD005187.
98. National Foundation for Infectious Diseases. Call to action: influenza immunization among health-care workers, 2003. Available at http://www.nfid.org/pdf/publications/fluhealthcarecta08.pdf. Accessed October 5, 2011.
99. Pavia AT. Mandate to protect patients from health care-associated influenza. Clin Infect Dis 2010;50:465-7.
100. Poland GA, Tosh P, Jacobson RM. Requiring influenza vaccination for health care workers: seven truths we must accept. Vaccine 2005; 23:2251-5.
101. CDC. 2009 Adult vaccination coverage. The National Health Interview Survey. Available at http://www.cdc.gov/vaccines/stats-surv/nhis/2009-nhis.htm. Accessed October 5, 2011.
102. LaVela SL, Smith B, Weaver FM, et al. Attitudes and practices regarding influenza vaccination among healthcare workers providing services to individuals with spinal cord injuries and disorders. Infect Control Hosp Epidemiol 2004;25:933-40.
103. Begue RE, Gee SQ. Improving influenza immunization among healthcare workers. Infect Control Hosp Epidemiol 1998;19:518-20.
104. Ofstead CL, Tucker SJ, Beebe TJ, et al. Influenza vaccination among registered nurses: information receipt, knowledge, and decision-making at an institution with a multifaceted educational program. Infect Control Hosp Epidemiol 2008;29:99-106.
105. Goldstein AO, Kincade JE, Gamble G, et al. Policies and practices for improving influenza immunization rates among healthcare workers. Infect Control Hosp Epidemiol 2004;25:908-11.
106. Ong AK, Srimanunthiphol J, Frankel RI. Influenza vaccination status of healthcare workers and the extent of their domestic contact with individuals at high risk for influenza-related complications. Infect Control Hosp Epidemiol 2000;21:735-7.
107. Weingarten S, Riedinger M, Bolton LB, et al. Barriers to influenza vaccine acceptance: a survey of physicians and nurses. Am J Infect Control 1989;17:202-7.
108. Hofmann F, Ferracin C, Marsh G, et al. Influenza vaccination of healthcare workers: a literature review of attitudes and beliefs. Infection 2006;34:142-7.
109. Hollmeyer HG, Hayden F, Poland G, et al. Influenza vaccination of health care workers in hospitals-a review of studies on attitudes and predictors. Vaccine 2009;27:3935-44.
110. Harbarth S, Siegrist CA, Schira JC, et al. Influenza immunization: improving compliance of healthcare workers. Infect Control Hosp Epidemiol 1998;19:337-42.
111. Nichol KLHauge M. Influenza vaccination of healthcare workers. Infect Control Hosp Epidemiol 1997;18:189-94.
112. Watanakunakorn C, Ellis G, Gemmel D. Attitude of healthcare personnel regarding influenza immunization. Infect Control Hosp Epidemiol 1993;14:17-20.
113. Bryant KA, Stover B, Cain L, et al. Improving influenza immunization rates among healthcare workers caring for high-risk pediatric patients. Infect Control Hosp Epidemiol 2004;25:912-7.
114. Bertin M, Scarpelli M, Proctor AW, et al. Novel use of the intranet to document health care personnel participation in a mandatory influenza vaccination reporting program. Am J Infect Control 2007;35:33-7.
115. Ajenjo MC, Woeltje KF, Babcock HM, et al. Influenza vaccination among healthcare workers: ten-year experience of a large healthcare organization. Infect Control Hosp Epidemiol 2010;31:233-40.
116. Manuel DG, Henry B, Hockin J, et al. Health behavior associated with influenza vaccination among healthcare workers in long-term-care facilities. Infect Control Hosp Epidemiol 2002;23:609-14.
117. Nafziger DA, Herwaldt LA. Attitudes of internal medicine residents regarding influenza vaccination. Infect Control Hosp Epidemiol 1994;15:32-5.
118. Ohrt CK, McKinney WP. Achieving compliance with influenza immunization of medical house staff and students. A randomized controlled trial. JAMA 1992;267:1377-80.
119. McArthur MA, Simor AE, Campbell B, et al. Influenza vaccination in long-term-care facilities: structuring programs for success. Infect Control Hosp Epidemiol 1999;20:499-503.
120. CDC. Interventions to increase influenza vaccination of health-care workers-California and Minnesota. MMWR 2005;54:196-9.
121. Polgreen PM, Septimus EJ, Parry MF, et al. Relationship of influenza vaccination declination statements and influenza vaccination rates for healthcare workers in 22 US hospitals. Infect Control Hosp Epidemiol 2008;29:675-7.
122. Talbot TR. Do declination statements increase health care worker influenza vaccination rates? Clin Infect Dis 2009;49:773-9.
123. Polgreen PM, Chen Y, Beekmann S, et al. Elements of influenza vaccination programs that predict higher vaccination rates: results of an emerging infections network survey. Clin Infect Dis 2008; 46:14-9.
124. CDC. Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-2).
125. Poland GA, Ofstead CL, Tucker SJ, et al. Receptivity to mandatory influenza vaccination policies for healthcare workers among registered nurses working on inpatient units. Infect Control Hosp Epidemiol 2008;29:170-3.
126. Babcock HM, Gemeinhart N, Jones M, et al. Mandatory influenza vaccination of health care workers: translating policy to practice. Clin Infect Dis 2010;50:459-64.
127. Joint Commission on Accreditation of Healthcare Organizations. New infection control requirement for offering influenza vaccination to staff and licensed independent practitioners. Jt Comm Perspect 2006;26:10-1.
128. National Quality Forum. National voluntary consensus standards for influenza and pneumococcal immunizations. Available at http://www.qualityforum.org/Publications/2008/12/National_Voluntary_Consensus_Standards_for_Influenza_and_Pneumococcal_Immunizations.aspx. Accessed October 5, 2011.
129. Govaert TM, Dinant GJ, Aretz K, et al. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ 1993;307:988-90.
130. Margolis KL, Nichol KL, Poland GA, et al. Frequency of adverse reactions to influenza vaccine in the elderly: a randomized, placebo-controlled trial. JAMA 1990;264:1139-41.
131. CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR 2011;60:1128-32.
132. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003-32.
133. CDC. Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011;60(No. RR-1).
134. Strebel PM, Papania MJ, Dayan GH, Halsey NA. Measles vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Philadelphia, PA: W.B. Saunders; 2008:353-98.
135. CDC. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998;47(No. RR-8).
136. CDC. Progress toward measles elimination-region of the Americas, 2002-2003. MMWR 2004;53:304-6.
137. Orenstein WA, Papania MH, Wharton ME. Measles elimination in the United States. J Infect Dis 2004;189(Suppl 1):S1-3.
138. World Health Organization. Measles fact sheet No.286. Available at http://www.who.int/mediacentre/factsheets/fs286/en/index.html. Accessed October 5, 2011.
139. CDC. Global measles mortality, 2000-2008. MMWR 2009; 58:1321-6.
140. CDC. Outbreak of measles-San Diego, California, January-February 2008. MMWR 2008;57:203-6.
141. Sugerman DE, Barskey, Delea MG, et al. Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated. Pediatrics 2010;125:747-55.
142. Parker AA, Staggs W, Dayan GH, et al. Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. N Engl J Med 2006;355:447-55.
143. CDC. Measles-United States, January-July 2008. MMWR 2008; 57:893-6.
144. Parker Fiebelkorn A, Redd SB, Gallagher, et al. Measles in the United States during the postelimination era. J Infect Dis 2010;202:1520-8.
145. Farizo KM, Stehr-Green PA, Simpson, DM, Markowitz LE. Pediatric emergency room visits-a risk factor for acquiring measles. Pediatrics 1991;87:74-9.
146. Rivera ME, Mason WH, Ross LA, Wright HT Jr. Nosocomial measles infection in a pediatric hospital during a community-wide epidemic. J Pediatr 1991;119:183-6.
147. CDC. Immunization administration requirements for hospital employees for MMR. Available at http://www2a.cdc.gov/nip/StateVaccApp/statevaccsApp/AdministrationbyVaccine.asp?Vaccinetmp=MMR. Accessed October 5, 2011.
148. CDC. Coverage estimates for school entry vaccinations for school year 2009-2010. School and childcare vaccination survey. Available at http://www2.cdc.gov/nip/schoolsurv/nationalavg.asp. Accessed October 5, 2011.
149. Chen SY, Anderson S, Kutty PK, et al. Health care-associated measles outbreak in the United States after an importation: challenges and economic impact. J Infect Dis 2011;203:1517-25.
150. Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee. Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. 2007. Am J Infect Control 2007;35(10 Suppl 2): S65-164.
151. Steingart KR, Thomas AR, Dykewicz CA, Redd SC. Transmission of measles virus in healthcare settings during a communitywide outbreak. Infect Control Hosp Epidemiol 1999;20:115-9.
152. LeBaron CW, Beeler J, Sullivan BJ, et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med 2007;161:294-301.
153. Willy ME, Kozoil DE, Fleisher T, et al. Measles immunity in a population of health-care workers. Infect Control Hosp Epidemiol 1994;15:12-7.
154. Schwarcz S, Mccaw B, Fukushima P. Prevalence of measles susceptibility in hospital staff: evidence to support expanding the recommendations of the Immunization Practices Advisory Committee. Arch Intern Med 1992;152:1481-3.
155. Houck P, Scottjohnson G, Krebs L. Measles immunity among community hospital employees. Infect Control Hosp Epidemiol 1991;12:663-8.
156. Wright LJ, Carlquist JF. Measles immunity in employees of a multihospital health-care provider. Infect Control Hosp Epidemiol 1994;15:8-11.
157. Weber DJ, Consoil S, Sickbert-Bennett E, Miller MB, Rutala WA. Susceptibility to measles, mumps, and rubella in newly hired (2006-2008) healthcare workers born before 1957. Infect Control Hosp Epidemiol 2010;31:655-7.
158. Braunstein H, Thomas S, Ito R. Immunity to measles in a large population of varying age-significance with respect to vaccination. Am J Dis Child 1990;144:296-8.
159. Smith E, Welch W, Berhow M, Wong VK. Measles susceptibility of hospital employees as determined by ELISA. Clin Res 1990;38:A183.
160. Kim M, LaPointe J, Liu FJ. Epidemiology of measles immunity in a population of healthcare workers. Infect Control Hosp Epidemiol 1992;13:399-402.
161. McQuillan GM, Kruszon-Moran D, Hyde TB, Forghani B, Bellini W, Dayan GH. Seroprevalence of measles antibody in the US population, 1999-2004. J Infect Dis 2007;196:1459-64.
162. Hutchins SS, Bellini WJ, Coronado V, Jiles R, Wooten K, Deladisma A. Population immunity to measles in the United States, 1999. J Infect Dis 2004;189:S91-7.
163. Brodsky L, Stanievich J. Sensorineural hearing loss following live measles virus vaccination. Int J Pediatr Otorhinolaryngol 1985; 10:159-63.
164. Marshall GS, Wright PF, Fenichel GM, Karzon DT. Diffuse retinopathy following measles, mumps, and rubella vaccination. Pediatrics 1985;76:989-991.
165. Kazarian EL, Gager W E. Optic neuritis complicating measles, mumps, and rubella vaccination. Am J Ophthalmol 1978;86:544-7.
166. daSilveira CM, Salisbury DM, deQuadros CA. Measles vaccination and Guillain-Barré syndrome. Lancet 1997;349(9044):14-6.
167. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Childhood vaccination and type 1 diabetes. N Engl J Med 2004;350:1398-404.
168. Bernstein CN, Rawsthorne P, Blanchard JF. Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease. Inflamm Bowel Dis 2007;13:759-62.
169. Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 2002;324(7334):393-6.
170. Grabowsky M, Markowitz L. Serologic screening, mass immunization, and implications for immunization programs. J Infect Dis 1991; 164:1237-8.
171. Subbarao EK, Amin S, Kumar ML. Prevaccination serologic screening for measles in health-care workers. J Infect Dis 1991;163:876-8.
172. Sellick JA, Longbine D, Schifeling R, Mylotte JM. Screening hospital employees for measles immunity is more cost-effective than blind immunization. Ann InternMed 1992;116:982-4.
173. Ammari LK, Bell LM, Hodinka R L. Secondary measles-vaccine failure in health-care workers exposed to infected patients. Infect Control Hosp Epidemiol 1993;14:81-6.
174. Dayan GH, Rota K, Bellini W, Redd S. Measles. In: CDC. Manual for the surveillance of vaccine-preventable diseases. Available at http://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.pdf. Accessed October 5, 2011.
175. Plotkin SA, Rubin SA. Mumps vaccine. In: Plotkin S, Orenstein W, Offit P, eds. Vaccines. 5th ed. Philadelphia, PA: W.B. Saunders; 2008:435-65.
176. CDC. Current trends mumps-United States, 1980-1983. MMWR 1983;32:545-7.
177. CDC. Mumps vaccine. MMWR 1977;26:393-4.
178. van Loon FPL, Holmes SJ, Sirotkin BI, et al. Mumps surveillance-United States, 1988-1993. MMWR 1995;44(No. SS-3).
179. CDC. Measles prevention. MMWR 1989;38(Suppl 9).
180. US Department of Health and Human Services. Healthy people 2010: understanding and improving health. Washington, DC: US Department of Health and Human Services; 2000.
181. CDC. Mumps epidemic-Iowa, 2006. MMWR 2006;55:366-8.
182. CDC. Multistate outbreak of mumps-United States, January 1-May 2, 2006. MMWR 2006;55:559-63.
183. Dayan GH, Quinlisk MP, Parker AA. Recent resurgence of mumps in the United States. N Engl J Med 2008;358:1580-9.
184. CDC. Mumps outbreak-New York and New Jersey, June 2009-January 2010. MMWR 2010;59:125-9.
185. Nelson G, Lizama-Aguon A, Quiambao E, et al. Third dose MMR intervention during a mumps outbreak in a highly-vaccinated population-Guam 2009-2010 [Presentation]. Presented at the 45th National Immunization Conference, Washington, DC; March 29, 2011.
186. Gordon JE, Kilham L. Ten years in the epidemiology of mumps. Am J Med Sci 1949;218:338-59.
187. Philip RN, Reinhard KR, Lackman DB, Observations on a mumps epidemic in a virgin population. Am J Hyg 1959;69:91-111.
188. CDC. Mumps. In: Atkinson, Wolfe C, Hamborsky J, eds. Epidemiology and prevention of vaccine-preventable diseases. Washington, DC: Public Health Foundation; 2009:189-98.
189. Meyer MB. An epidemiologic study of mumps: its spread in schools and families. Am J Hyg 1962;75:259-81.
190. Harris RW, Kehrer AF, Isacson P. Relationship of occupations to risk of clinical mumps in adults. Am J Epidemiol 1969;89:264-70.
191. Wharton M, Cochi SL, Hutcheson RH, Schaffner W. Mumps transmission in hospitals. Arch Intern Med 1990;150:47-9.
192. Fischer PR, Brunetti C, Welch V, Christenson JC. Nosocomial mumps: report of an outbreak and its control. Am J Infect Control 1996;24:13-8.
193. Bonebrake AL, Silkaitis C, Monga G, et al. Effects of mumps outbreak in hospital, Chicago, Illinois, USA, 2006. Emerg Infect Dis 2010;16:426-32.
194. CDC. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) for the control and elimination of mumps. MMWR 2006;55:629-30.
195. Weber SH, Merkel D, Miller P, Tilzer L, Kliethermes J, Horvat R. Hospital and clinical laboratory response to mumps exposures. Labmedicine 2007;38:285-8.
196. Galazka AM, Robertson SE, Kraigher A, Mumps and mumps vaccine: a global review. Bull World Health Organ 1999;77:3-14.
197. Hersh BS, Fine PE, Kent WK, et al. Mumps outbreak in a highly vaccinated population. J Pediatr 1991;119:187-93.
198. Cheek JE, Baron R, Atlas H, Wilson DL, Crider RD. Mumps outbreak in a highly vaccinated school population: evidence for large-scale vaccination failure. Arch Pediatr Adolesc Med 1995;149:774-8.
199. Schaffzin JK, Pollock L, Schulte C, et al. Effectiveness of previous mumps vaccination during a summer camp outbreak. Pediatrics 2007;120:e862-8.
200. Cohen C, White JM, Savage EJ, et al. Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg Infect Dis 2007; 13:12-7.
201. Harling R, White JM, Ramsay ME, Macsween KF, van den Bosch C. The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine 2005;23:4070-4.
202. Marin M, Quinlisk P, Shimabukuro T, Sawhney C, Brown C, Lebaron CW. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students-Iowa, 2006. Vaccine 2008; 26:3601-7.
203. Davidkin I, Valle M, Julkunen I, Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up. Vaccine 1995;13:1617-22.
204. Rubin SA, Qi L, Audet SA. et al. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis 2008;198:508-15.
205. Date AA, Kyaw MH, Rue AM, et al. Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population. J Infect Dis 2008;197:1662-8.
206. Cortese MM, Jordan HT, Curns AT, et al. Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis 2008;46:1172-80.
207. Kutty PK, Kruszon-Moran DM, Dayan GH, et al. Seroprevalence of antibody to mumps virus in the US population, 1999-2004. J Infect Dis 2010;202:667-74.
208. Brunell PA, Brickman A, O'Hare D, Steinberg S. Ineffectiveness of isolation of patients as a method of preventing the spread of mumps. Failure of the mumps skin-test antigen to predict immune status. N Engl J Med 1968;279:1357-61.
209. Kutty PK, Kyaw MH, Dayan GH, et al. Guidance for isolation precautions for mumps in the United States: a review of the scientific basis for policy change. Clin Infect Dis 2010;50:1619-28.
210. Wharton M, Cochi SL, Hutcheson RH, Bistowish JM, Schaffner W. A large outbreak of mumps in the postvaccine era. J Infect Dis 1988;158:1253-60.
211. Plotkin SA, Reef SE. Rubella vaccine. In: Plotkin S, Orenstein W, Offit P, eds. Vacciness 5th ed. Philadelphia, PA: W.B. Saunders; 2008:735-71.
212. Bosma TJ, Etherington J, O'Shea S, et al. Rubella virus and chronic joint disease: is there an association? J Clin Microbiol 1998;36:3524-6.
213. American Academy of Pediatrics. Rubella. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. 2009 red book: report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009:579-84.
214. Green RH, Balsamo MR, Giles JP, Krugman S, Mirick GS. Studies of the natural history and prevention of rubella. Am J Dis Child 1965;110:348-65.
215. Ingalls TH, Plotkin SA, Meyer HM Jr, Parkman PD. Rubella: epidemiology, virology, and immunology. Am J Med Sci 1967; 253:349-73.
216. Orenstein WA, Bart KJ, Hinman AR, et al. The opportunity and obligation to eliminate rubella from the United States. JAMA 1984;251:1988-94.
217. Williams NM, Preblud SR. Rubella and congenital rubella surveillance, 1983. MMWR 1984;33(No. SS-4):1-10.
218. Cochi SL, Edmonds LE, Dyer K, et al. Congenital rubella syndrome in the United States, 1970-1985: on the verge of elimination. Am J Epidemiol 1989;129:349-61.
219. CDC. Achievements in public health: elimination of rubella and congenital rubella syndrome-United States, 1969- 2004. MMWR 2005;54:279-82.
220. Reef SE, Cochi SL. The evidence for the elimination of rubella and congenital rubella syndrome in the United States: a public health achievement. Clin Infect Dis 2006;43(Suppl 3):S123-5.
221. Greaves WL, Orenstein WA, Stetler HC, Preblud SR, Hinman AR, Bart KJ. Prevention of rubella transmission in medical facilities. JAMA 1982;248:861-4.
222. Gladstone JL. Rubella exposure in an obstetric clinic. Obstet Gynecol 1981;57:182-6.
223. CDC. Nosocomial rubella infection-North Dakota, Alabama, Ohio. MMWR 1981;29:629-31.
224. CDC. Exposure of patients to rubella by medical personnel-California. MMWR 1978;27:123.
225. Strassburg MA, Imagawa DT, Fannin SL, et al. Rubella outbreak among hospital employees. Obstet Gynecol 1981;57:283-8.
226. Fliegel PE, Weinstein WM. Rubella outbreak in a prenatal clinic: management and prevention. Am J Infect Control 1982;10:29-33.
227. Polk BF, White JA, DeGirolami PC, Modlin JF. An outbreak of rubella among hospital personnel. N Engl J Med 1980;303:541-5.
228. McLaughlin MC, Gold LH. The New York rubella incident: a case for changing hospital policy regarding rubella testing and immunization. Am J Public Health 1979;69:287-9.
229. CDC. Rubella in hospital personnel and patients-Colorado. MMWR 1979;28:325-7.
230. Heseltine PNR, Ripper M, Wohlford P. Nosocomial rubella: consequences of an outbreak and efficacy of a mandatory immunization program. Infect Control 1985;6:371-4.
231. CDC. Epidemiologic notes and reports rubella in hospitals-California. MMWR 1983;32:37-9.
232. Papania M, Reef S, Jumaan A, Linigappa JR, Williams WW. Nosocomial measles, mumps, rubella, and other viral infections. In: Mayhall CG, ed. Hospital epidemiology and infection control. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:829-49.
233. de Valk H, Rebière I. [Epidemic of rubella: evaluation of the vaccine efficacy on the ground]. Saint Maurice, France: Réseau National de Santé Publique; 1998:1-52.
234. Weibel RE, Carlson AJ Jr, Villarejos VM, et al. Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus. Proc Soc Exp Biol Med 1980;165:323-6.
235. Balfour HH, Groth KE, Edelman CK, RA 27/3 rubella vaccine-a four-year follow-up. Am J Dis Child, 1980;134:350-3.
236. Weibel RE, Villarejos VM, Klein EB, Buynak EB, McLean AA, Hilleman MR. Clinical and laboratory studies of live attenuated RA 27/3 and HPV 77-DE rubella virus vaccines. Proc Soc Exp Biol Med 1980;165:44-9.
237. Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 2008;197:950-6.
238. LeBaron CW, Forghani B, Matter L, et al. Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009;200:888-99.
239. Hyde TB, Kruszon-Moran D, McQuillan GM, Cossen C, Forghani B, Reef SE. Rubella immunity levels in the United States population: has the threshold of viral elimination been reached? Clin Infect Dis 2006;43(Suppl 3):S146-50.
240. Fraser V, Spitznagel E, Medoff G, Dunagan WC. Results of a rubella screening program for hospital employees: a five-year review (1986-1990). Am J Epidemiol 1993;138:756-64.
241. Hartstein AI, Quan MA, Williams ML, Osterud HT, Foster LR. Rubella screening and immunization of health care personnel: critical appraisal of a voluntary program. Am J Infect Control 1983;11:1-9.
242. Weiss KE, Flavo CD, Buimovici-Klein E, Magill JW, Cooper LZ. Evaluation of an employee health service as a setting for a rubella screening and immunization program. Am J Public Health 1979;69:281-3.
243. CDC. Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. MMWR 2001;50:1117.
244. CDC. Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. MMWR 2001;50(No. RR-12).
245. Schiff GM. Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. Am J Dis Child 1969;118:322-7.
246. Mortimer EA Jr. Pertussis vaccine. In: Plotkin SA, Mortimer EA, eds. Vaccines. 2nd ed. Philadelphia, PA: W.B. Saunders; 1994:94.
247. Mortimer EA Jr. Pertussis and its prevention: a family affair. J Infect Dis 1990;161:473-9.
248. CDC. Updated Tdap vaccination coverage rates. 2009 Adult vaccination coverage, National Interview Survey. Available at http://www.cdc.gov/vaccines/stats-surv/nhis/2009-nhis.htm. Accessed October 5, 2011.
249. Christie C, Glover AM, Willke MJ, Marx ML, Reising SF, Hutchinson NM. Containment of pertussis in the regional pediatric hospital during the greater Cincinnati epidemic of 1993. Infect Control Hosp Epidemiol 1995;16:556-63.
250. Kurt TL, Yeager AS, Guennette S, Dunlop S. Spread of pertussis by hospital staff. JAMA 1972;221:264-7.
251. Linnemann CC, Ramundo N, Perlstein PH, et al. Use of pertussis vaccine in an epidemic involving hospital staff. Lancet 1975;2:540-3.
252. Valenti WM, Pincus PH, Messner MK. Nosocomial pertussis: possible spread by a hospital visitor. Am J Dis Child 1980;134:520-1.
253. Deville JG, Cherry JD, Christenson PD, et al. Frequency of unrecognized Bordetella pertussis infections in adults. Clin Infect Dis 1995;21:639-42.
254. Wright SW, Decker MD, Edwards KM. Incidence of pertussis infection in healthcare workers. Infect Control Hosp Epidemiol 1999; 20:120-3.
255. Calugar A, Ortega-Sánchez IR, Tiwari T, Oakes L, Jahre JA, Murphy TV. Nosocomial pertussis: costs of an outbreak and benefits of vaccinating health care workers. Clin Infect Dis 2006;42:981-8.
256. Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353:1555-63.
257. Rank C, Quinn HE, McIntyre PB. Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Pediatr Infect Dis J 2009;28:152-3.
258. Wei SC, Tatti K, Cushing K, et al. Effectiveness of adolescent and adult tetanus, reduced diphtheria, and acellular pertussis vaccine (Tdap) against pertussis. Clin Infect Dis 2010;51:315-21.
259. Klein NP, Hansen J, Lewis E, et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. Pediatr Infect Dis J 2010;29:613-7.
260. Blatter M, Friedland LR, Weston WM, Li P, Howe B. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine 2009;27:765-72.
261. Pichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005;293:3003-11.
262. Jackson LA, Yu O, Nelson J, et al. Risk of medically attended local reactions following diphtheria toxoid containing vaccines in adolescents and young adults: a Vaccine Safety Datalink study. Vaccine 2009;27:4912-6.
263. Yih WK, Nordin JD, Kulldorff M, et al. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine 2009;27:4257-62.
264. Goins W, Edwards KM, Vnencak-Jones CL, et al. Comparison of two strategies to prevent pertussis in vaccinated healthcare personnel following pertussis exposure [Presentation]. Presented at the International Conference of Healthcare-Associated Infections, Atlanta, Georgia; March 18-22, 2010.
265. Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996;17:53-80.
266. CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56 (No. RR-4).
267. Guris D, Jumaan AO, Mascola L, et al. Changing varicella epidemiology in active surveillance sites-United States, 1995-2005. J Infect Dis 2008;197(Suppl 2):S71-75.
268. Lopez AS, Zhang J, Brown C, Bialek S. Varicella-related hospitalizations in the United States, 2000-2006: the 1-dose varicella vaccination era. Pediatrics 2011;127:238-45.
269. Marin M, Zhang JX, Seward JF. Near elimination of varicella deaths in the US following implementation of the childhood vaccination program. Pediatrics 2011;128:214-20.
270. Kattan JA, Sosa LE, Bohnwagner HD, Hadler JL. Impact of 2-dose vaccination on varicella epidemiology: Connecticut-2005-2008. J Infect Dis 2011;203:509-12.
271. Reynolds M, Kruszon-Moran D, Jumaan AO, Schmid DS, McQuillan GM. Varicella seroprevalence in the United States: data from the National Health and Nutrition Examination Survey (NHANES), 1999-2004. Public Health Rep 2010;125:860-9.
272. Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO. Contagiousness of varicella in vaccinated cases: a household contact study. JAMA 2004;292:851-5.
273. Saiman L, LaRussa P, Steinberg SP, et al. Persistence of immunity to varicella-zoster virus vaccination among health care workers. Infect Control Hosp Epidemiol 2001;22:279-83.
274. Ampofo K, Saiman L, LaRussa P, Steinberg S, Annunziato P, Gershon A. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis 2002;34:774-9.
275. Lee BW. Review of varicella zoster seroepidemiology in India and Southeast Asia. Trop Med Int Health 1998;3:886-90.
276. Longfield JN, Winn Re, Gibson RL, Juchau SV, Hoffman PV. Varicella outbreak in army recruits from Puerto Rico. Varicella susceptibility in a population from the tropics. Arch Intern Med 1990;150:970-3.
277. Meyers JD, MacQuarrie MB, Merigan TC, Jennison MH. Varicella. Part 1: outbreak in oncology patients at a children's hospital. West J Med 1979;130:196-9.
278. Gustafson TL, Shehab Z, Brunell PA. Outbreak of varicella in a newborn intensive care nursery. Am J Dis Child 1984;138:548-50.
279. Hyams PJ, Stuewe MCS, Heitzer V. Herpes zoster causing varicella (chicken pox) in hospital employees: cost of a casual attitude. Am J Infect Control 1984;12:2-5.
280. Weitekamp MR, Schan P, Aber RC. An algorithm for the control of varicella-zoster virus. Am J Infect Control 1985;13:193-8.
281. Alter SJ, Hammond JA, McVey CJ, Myers MG. Susceptibility to varicella-zoster virus among adults at high risk for exposure. Infect Control 1986;7:448-51.
282. Krasinski K, Holzman RS, LaCouture R, Florman A. Hospital experience with varicella-zoster virus. Infect Control 1986;7:312-6.
283. Weber DJ, Rutala WA, Parham C. Impact and costs of varicella prevention in a university hospital. Am J Public Health 1988; 78:19-23.
284. Asano Y, Iwayama S, Miyata T, et al. Spread of varicella in hospitalized children having no direct contact with an indicator zoster case and its prevention by a live vaccine. Biken J 1980;23:157-61.
285. Leclair JM, Zaia JA, Levine MJ, Congdon RG, Goldmann DA. Airborne transmission of chickenpox in a hospital. N Engl J Med 1980;302:450-3.
286. Gustafson TL, Lavely GB, Brawner ER, Hutcheson RH, Wright PF, Schaffner W. An outbreak of airborne varicella. Pediatrics 1982; 70:550-6.
287. Josephson A, Gombert ME. Airborne transmission of nosocomial varicella from localized zoster. J Infect Dis 1988;158:238-41.
288. Sawyer MH, Chamberlin CJ, Wu YN, Aintablian N, Wallace MR. Detection of varicella-zoster virus DNA in air samples from hospital room. J Infect Dis 1994;169:91-4.
289. Behrman A, Schmid DS, Crivaro A, Watson B. A cluster of primary varicella cases among healthcare workers with false-positive varicella zoster virus titers. Infect Control Hosp Epidemiol 2003;24:202-6.
290. Adler AL, Casper C, Boeckh M, Heath J, Zerr DM. An outbreak of varicella with likely breakthrough disease in a population of pediatric cancer patients.Infect Control Hosp Epidemiol 2008;29:866-70.
291. Lopez SA, Burnett-Hartman A, Nambiar R, et al. Transmission of a newly characterized strain of varicella-zoster virus from a patient with herpes zoster in a long-term-care facility, West Virginia, 2004. J Infect Dis 2008;197:646-53.
292. Haiduven-Griffiths D, Fecko H. Varicella in hospital personnel: a challenge for the infection control practitioner. Am J Infect Control 1987;15:207-11.
293. Seward JF, Marin M, Vazquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis 2008;197(Suppl):S82-9.
294. Shapiro ED, Vazquez M, Esposito D, et al. Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis 2011;203:312-5
295. Merck & Co., Inc. VARIVAX [Package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 1995.
296. Gershon AA, Steinberg SP, LaRussa P, Ferrara A, Hammerschlag M, Gelb L. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 1988;158:132-7
297. Zerboni L, Nader S, Aoki K, Arvin AM. Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J Infect Dis 1998;177:1701-4.
298. Chaves SS, Haber P, Walton K, Wise RP, Izurieta HS, Schmid DS, Seward JF. Safety of varicella vaccine after licensure in the United States: experience from reports to the Vaccine Adverse Event Reporting System, 1995-2005. J Infect Dis. 2008;197(Suppl):S170-7.
299. Gershon AA, Takahashi M, Seward JF. Varicella vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Philadelphia, PA: W.B. Saunders. In press.
300. Lopez AS, Marin M. Strategies for the control and investigation of varicella outbreaks, 2008. Available at http://www.cdc.gov/vaccines/vpd-vac/varicella/outbreaks/manual.htm. Accessed October 5, 2011.
301. American Academy of Pediatrics. Varicella-zoster. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. 2009 red book: report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009:714-27.
302. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010;50:184-91.
303. CDC. Guideline for isolation precautions in hospitals. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC) and the National Center for Infectious Diseases. Infect Control Hosp Epidemiol 1996;17:53-80.
304. CDC. Occupational transmission of Neisseria meningitidis-California, 2009. MMWR 2010:59;1480-3.
305. CDC. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005;54(No. RR-7).
306. CDC. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010;59:273.
307. CDC. Updated recommendations for use of meningococcal conjugate vaccines-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2011;60:72-6.
308. Wu HM, Harcourt BH, Hatcher CP, et al. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. New Eng J Med 2009;360:886-92.
309. Lynch MF, Blanton EM, Bulens S, et al. Typhoid fever in the United States, 1999-2006. JAMA. 2009;302:859-65.
310. Steinberg EB, Bishop RB, Dempsey AF, et al. Typhoid fever in travelers: who should be targeted for prevention? Clin Infect Dis 2004; 39:186-91.
311. Crump JA, Kretsinger K, Gay K, et al. Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States FoodNet Multicenter retrospective Cohort Study. Antimicrob Agents Chemother 2008; 52:1278-84.
312. Crump JA, Barrett TJ, Nelson JT, et al. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and non-Typhi Salmonellae. Antimicrobial Resistance 2003;37:75-81.
313. CDC. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): human isolates final report, 2008. Atlanta, GA: US Department of Health and Human Services, CDC; 2010.
314. Gupta S, Medalla F, Omondi MW, et al. Laboratory-based surveillance for paratyphoid fever in the United States: travel and antimicrobial resistance. Clin Infect Dis 2008;46:1656-63.
315. Mermin JH, Townes JM, Gerber M, et al. Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med 1998;158:633-8.
316. CDC. Typhoid immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1994;43 (No. RR-14).
317. Bhattarai A, Mintz E. Typhoid and paratyphoid. In: CDC health information for international travel 2012. New York, NY: Oxford University Press; 2012.
318. Begier EM, Burwen DR, Haber P, Ball R. Vaccine Adverse Event Reporting System Working Group. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through 2002. Clin Infect Dis 2004;38:771-9.
319. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992:14:568-79.
320. CDC. Certification of poliomyelitis elimination-the Americas, 1994. MMWR 1994;43:720-2.
321. CDC. Poliomyelitis prevention in the United States. MMWR 2000;49(No. RR-5).
322. Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004;292:1696-701.
323. CDC. Imported vaccine-associated paralytic poliomyelitis-United States, 2005. MMWR 2006;55:97-9.
324. DeVries AS, Harper J, Murray A, et al. Neuroinvasive immunodeficiency-associated vaccine-derived poliomyelitis twelve years after infection-Minnesota, 2008. N Engl J Med 2011;364:2316-23.
325. Alexander JP, Jr., Ehresmann K, Seward J, et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis 2009;199:391-7.
326. Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 1997;16:312-22.
327. CDC. Recommended adult immunization schedule-United States, 2011. MMWR 2011;60:1-4.
328. Briss PA, Rodewald LE, Hinman AR, et al. Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults. The Task Force on Community Preventive Services. Am J Prev Med 2000;18(1 Suppl):97-140.
329. Kroger A, Atkinson W. General recommendations for vaccination and immunoprophylaxis. In: CDC. CDC health information for international travel 2012. New York, NY: Oxford University Press; 2012.